Business Context and Reporting Period
This Form 8-K Current Report was filed by BioCardia, Inc. (BCDA) on October 2, 2025. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
On October 2, 2025, the Company received formal written notice from The Nasdaq Stock Market, LLC's Staff confirming that it has regained compliance with Listing Rule 5550(b)(1) (the "Equity Rule"). Consequently, the Company's common stock will continue to be listed on The Nasdaq Stock Market.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the resolution of the listing compliance issue. The primary contingency addressed was the potential delisting, which has been resolved.
Investor Verification Checklist
- Verify the continued listing status of BCDA on The Nasdaq Capital Market.
- Review the attached press release (Exhibit 99.1) for details on the specific compliance measures taken.
- Confirm that no other pending regulatory actions exist regarding the company's listing status.